Synlogic Stock Financial Health and Shareholder Returns

Synlogic stock has shown a mixed performance in terms of financial health and shareholder returns. The company's net loss has been significant, with a net loss of $43.6 million in 2020 and $33.9 million in 2019.

Synlogic's revenue has been minimal, with total revenue of $1.3 million in 2020. This is a significant decrease from 2019, when the company had total revenue of $3.3 million.

Despite the company's financial struggles, Synlogic has made significant progress in its research and development efforts. The company has been working on several programs aimed at developing novel therapeutics for diseases such as phenylketonuria and Clostridioides difficile infection.

Synlogic's financial situation is quite straightforward. The company makes less than $1 million in revenue, indicating a relatively small operation.

This lack of revenue is reflected in the company's market capitalization, which is a mere $21 million. This is a fraction of what many other companies in the industry are worth.

Synlogic's financial situation is also characterized by its complete lack of debt. The company has been debt-free for the past 5 years, which is a significant advantage in terms of financial stability.

In terms of price volatility, Synlogic's stock has been relatively stable in recent months, with an average weekly movement of 7.8%. This is lower than the market average of 6.5% and the biotech industry average of 10.8%.

Synlogic, Inc. is a biopharmaceutical company that focuses on discovering and developing synthetic biotics to treat metabolic diseases in the United States.

The company has a small team with only one employee, led by CEO Mary Dooley. You can find more information about Synlogic on their official website, www.synlogictx.com.

Synlogic is based in Winchester, Massachusetts, and has a collaboration agreement with notable companies F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., as well as Ginkgo Bioworks, Inc.

Their pipeline includes several promising drug candidates, such as SYNB1618 for the treatment of phenylketonuria, and SYNB8802 for the treatment of enteric hyperoxaluria.

Synlogic has a solid financial foundation, with a debt-to-equity ratio of 0% due to its total shareholder equity of $12.6M and a total debt of $0.0. This means the company is debt-free.

Its total assets are $17.4M, which is significantly higher than its total liabilities of $4.8M. This suggests that Synlogic has a stable financial position.

Here are some key financial metrics for Synlogic:

Synlogic has a strong cash position, with $17.03m in cash reserves. This is a significant advantage for the company, allowing it to invest in its business and weather any financial storms.

Shareholder Returns are a key indicator of a company's financial health. SYBX has exceeded the US Biotechs industry, returning 23.7% over the past year.

The industry average return was 2.7% over the same period. This significant difference suggests that SYBX has been performing better than its peers.

Here's a comparison of SYBX's returns with the US Market and the US Biotechs industry over the past year:

In terms of return, SYBX has exceeded the US Market, which returned 16.7% over the past year. This is a notable achievement and suggests that SYBX has been a strong performer in the market.

Explore further: Stock Market

Synlogic has a solid financial foundation, with a total shareholder equity of $12.6M and no debt, giving it a debt-to-equity ratio of 0%. It's a great sign to see a company with no debt.

The company's total assets and total liabilities are $17.4M and $4.8M respectively, indicating a strong balance sheet. Synlogic has sufficient cash runway for more than 3 years based on its current free cash flow.

Here's a breakdown of Synlogic's cash runway:

Synlogic has not had any debt for the past 5 years, demonstrating a commitment to financial stability. Its current free cash flow suggests that it can continue to operate without taking on new debt.

Synlogic stock has been a topic of interest for many investors.

The company has a strong focus on developing novel therapeutics, with a pipeline that includes several programs targeting diseases such as Clostridioides difficile (C. diff) and phenylketonuria (PKU).

Synlogic's proprietary platform, known as the "Synlogic platform", uses a combination of synthetic biology and microbiome engineering to develop these treatments.

One of the key benefits of this approach is that it allows for the development of targeted therapies that can specifically address the root causes of disease.

Synlogic's lead program, SYNB1618, is a promising treatment for C. diff, a bacterial infection that can be life-threatening in severe cases.

In preclinical studies, SYNB1618 has shown impressive results, with a 100% cure rate in mice with C. diff.

Synlogic stock has had its fair share of ups and downs over the years.

The all-time high Synlogic stock closing price was a whopping 990.15 on December 17, 2015.

The current 52-week high stock price is 1.96, which is 14% above the current share price.

The average Synlogic stock price for the last 52 weeks is 1.38.

If you're looking at the stock's performance over time, here are some key statistics:

The company has seen significant growth in earnings over the years, with a 14.5% annual growth rate over the past 5 years.

A fresh viewpoint: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically